- Poster presentation
- Open Access
Coronary sinus flow reserve in response to cold pressor stress in healthy women using velocity-encoded cine (VEC) spiral 3 T MRI
© Maroules et al; licensee BioMed Central Ltd. 2009
- Published: 28 January 2009
- Myocardial Blood Flow
- Coronary Sinus
- Obstructive Coronary Artery Disease
- Cold Pressor Test
- Hypertensive Heart Disease
Despite the overwhelming focus on obstructive coronary artery disease over the last few decades, considerable cardiovascular morbidity and mortality is caused by diffuse, non-obstructive disease for which traditional cardiovascular imaging techniques are not suitable. Novel noninvasive techniques that can detect changes in global myocardial perfusion and function might improve the clinical management of patients with diffuse cardiac disease. Coronary sinus flow imaging by velocity-encoding cine MRI has previously been described as a useful measure of global left ventricular perfusion in patients with heart failure, hypertensive heart disease, and cardiac transplants. To our knowledge, this technique has not been investigated using a spiral 3 T MRI technique, which could potentially enhance vessel wall delineation and accelerate scan time.
Prior studies have demonstrated an increase in coronary sinus flow in response to pharmagologic stress. This study tested whether the cold pressor test (CPT), a more specific test of endothelial reactivity could provoke measurable changes in coronary sinus flow.
To determine the feasibility of coronary sinus flow imaging in healthy women in response to the cold pressor test (CPT) using velocity-encoding cine (VEC) spiral 3 T MRI.
Velocity-encoding cine spiral 3 T MRI is a promising tool for evaluating coronary sinus flow reserve. The CPT provokes a significant increase in myocardial blood flow which can be used to specifically evaluate endothelial function. Future studies will examine the ability of this technique to detect meaningful changes in myocardial flow reserve.
This article is published under license to BioMed Central Ltd.